Treatment

Debio 0123 and Sacituzumab govitecan clinical trials

1 indexed studies · 0 currently recruiting

Active not recruitingPHASE1, PHASE2
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
This study is testing a new combination of two drugs, Debio0123 and Sacituzumab govitecan, for people with advanced triple-negative breast cancer (TNBC) or hormone-receptor-positive/HER2-negative (HR+/HER2-) breast cancer. It aims to see if this treatment is safe and effective.
For: Advanced Breast Cancer
Spain · United Kingdom